In patients with NAFLD, weight loss (median −3.61 kg) achieved within the 6-month program was associated with significant improvements in ALT levels, liver steatosis, histologic NAFLD activity score, liver stiffness, and the disappearance of NASH [66]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.